ALRN - Aileron Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.37
-0.02 (-0.84%)
As of 1:16PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.39
Open2.39
Bid2.39 x 1100
Ask2.41 x 1200
Day's Range2.37 - 2.59
52 Week Range1.98 - 13.74
Volume32,842
Avg. Volume100,907
Market Cap34.928M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.25
Trade prices are not sourced from all markets
  • GlobeNewswire5 hours ago

    Aileron Announces Poster Presentations at Two Scientific Conferences in November

    Aileron Therapeutics (ALRN), the clinical stage leader in the discovery and development of engineered cell-penetrating peptides, today announced that two abstracts for the company’s lead drug, ALRN-6924, will be presented, one each at the Society for Immunotherapy of Cancer (SITC) and the 2018 EORTC/NCI/AACR Symposium in November.

  • GlobeNewswirelast month

    Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, MD, PhD, has been named President and Chief Executive Officer and elected to its Board of Directors. “I am very excited to take on this new responsibility at Aileron as we further expand the clinical development of our lead product candidate, ALRN-6924, into combination therapies.  ALRN-6924 represents the proof-of-concept for Aileron’s stapled peptide technology, which I believe to be capable of producing additional novel drug candidates that address previously undruggable targets,” said Dr. Aivado.

  • GlobeNewswire2 months ago

    Aileron Therapeutics Reports Second Quarter 2018 Financial Results

    “In our clinical and preclinical programs to-date, ALRN-6924 has been shown to act on-target and to have antitumor activity. Further, in the second quarter, we completed a number of preclinical in-vivo studies with ALRN-6924 in combination with CDK4/6 inhibitors, IO drugs, and chemotherapeutic agents in solid and liquid tumors,” said Manuel Aivado, SVP, CSO and CMO of Aileron.  “It was gratifying to see impressive complementary activity between ALRN-6924 and a number of cancer therapeutics in these models.

  • GlobeNewswire3 months ago

    Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference

    Aileron Therapeutics (ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, SVP and Chief Medical Officer, will present at the Canaccord Genuity 38th Annual Growth Conference being held in Boston, MA. Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and other diseases. Stapled peptides are chemically stabilized alpha-helical peptides that are modified to improve their stability and cell penetrability while maintaining high affinity for large protein surfaces.

  • GlobeNewswire3 months ago

    Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018

    Aileron Therapeutics (ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that the Company will report its second quarter 2018 financial results on Tuesday, August 7, 2018 after the close of market. Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and other diseases. Stapled peptides are chemically stabilized alpha-helical peptides that are modified to improve their stability and cell penetrability while maintaining high affinity for large protein surfaces.